Sylvant siltuximab regulatory update

The European Commission approved an MAA from Johnson & Johnson's Janssen-Cilag International N.V. subsidiary for Sylvant siltuximab to treat multicentric Castleman's disease (MCD) in patients who are HIV-negative and human herpes virus 8 (HHV-8)-negative. Janssen plans to initially launch Sylvant in mid-June in the U.K., Germany, Austria, the Netherlands and Liechtenstein. Later this year Janssen will launch the product in Denmark, Finland, Sweden, Iceland, Norway and Switzerland. The company declined to disclose pricing information. ...